The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)

Consolidated Financial Statements for the Third Quarter Ended December 31, 2021
FY2022 (April 1, 2021 – March 31, 2022) [UNAUDITED]
February 10, 2022
Takara Bio Inc.
Tokyo Stock Exchange (1st section)4974
https://www.takara-bio.co.jp
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, Head of Corporate
Management Division
Tel. (077) 565-6970
Scheduled date of quarterly statement filing:
February 14, 2022
Scheduled date of starting delivery of dividends:
Supplementary documents of the financial results:
Yes
Financial results information meeting:No
Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles andpractices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.
Company name:
Stock exchange listings:
Code number:
URL:
Company representative:
Contact:

1. Results for the nine months ended December 31, 2021 (Apr. 1, 2021 – December 31, 2021)(1) Consolidated operating results(Percentages indicate changes from the same period of the previous fiscal year.)Nine months ended
Dec. 31, 2021
Net sales
Operating profit
Ordinary profit
Net income (loss) attributable to owners ofparent
Net income per share (in yen)
Fully diluted net income per share (in yen)
(Note) Comprehensive income(Millions of yen)
45,65919,926
20,154
14,364119.2917,080Nine months ended
Dec. 31, 2020
54.5
126.7
126.0
150.8

(Millions of yen)
29,549
8,791
8,919
5,726

20.3
126.6
128.9
111.4

245.7

47.56
4,940

226.6

(%)

(%)

(2) Consolidated financial position

Total assets
Net assets
Equity ratio (%)
Net assets per share (in yen)
(Reference) Equity

As of Dec. 31, 2021
(Millions of yen)

As of Mar 31, 2021
(Millions of yen)

106,116
89,45584.1
741.3589,27089,75074,30282.7
616.0574,181

2. Dividends
Annual dividends per share in yen
Year ending
Mar. 31, 2022 (Forecast)First quarter end
Second quarter end
0.00
0.00
Third quarter end
Year end
16.00
30.00
Annual16.00
30.00(Note) Revision of dividend payment forecast since the most recently announced payment forecast: Yes
Year ended
Mar. 31, 2021

Year ending
Mar. 31, 2022

The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)
3. Forecast for the year ending March 31, 2022 (Apr. 1, 2021 – Mar. 31, 2022)(Percentages indicated changes from the same period of the previous fiscal year.)Year ending Mar. 31, 2022
(Millions of yen)

Net sales
65,000Operating profit
26,000Ordinary profit
26,200Net income attributable to owners of the parent
18,500Net income per share (in yen)
153.63[Note] Revision of financial forecast since the most recently announced payment forecast: Yes
※

(%)
41.0
86.3
85.0
93.8

Others(1) Changes in subsidiaries during the nine months ended December 31, 2021
(Changes in specified subsidiaries resulting in change of scope) ： No
Newly included: － (Name)
Excluded: － (Name)(2) Application of special accounting methods to the consolidated quarterly financial statements: No(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
1) Changes based on revisions of accounting standard： Yes
2) Changes in accounting policies other than 1)： No
3) Changes in accounting estimates： No4) Restatement： No
NOTE: For details, please refer to "(4) Notes to Consolidated Quarterly Financial Statements (Changes in
Accounting Policies)" of "2. Consolidated Quarterly Financial Statements and Primary Notes" on page 9 of theattached material.
(4) Number of outstanding shares (Common stock)1) Number of outstanding shares at year end (Treasury stocks are included)
120,415,600
As of December 31, 2021
As of March 31, 2021
120,415,600
2) Number of treasury stocks at year end
As of December 31, 2021
As of March 31, 2021
3) Average number of outstanding shares
120,415,600
As of December 31, 2021
120,415,600
As of December 31, 2020※

These quarterly financial statements are not subject to auditing.

※Comment regarding appropriate use of earnings forecasts and other special notes
Forward-looking statements contained in this document are determined by the Takara Bio Inc. (the “Company”) based on
information currently available to the Company and include a number of uncertainties. Actual results could differ fromthese forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to“1. Overview of Financial Results for the nine months ended December 31, 2021 (4) Qualitative Information Regarding
Consolidated Forecasts”, on page 2 of the attached document.

The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)
Contents of the attached document
1. Overview of Financial Results for the nine months ended December 31, 2021……………………………………………...
(1) Overview of Financial Results……………………………………………………….………….………….………….....
(2) Overview of Financial Position………………………………………………...…………………………...…….............
(3) Overview of Cash Flows…………………………………………………………….…………………………….……...
(4) Qualitative Information Regarding Consolidated Forecasts..……………………………………………………………..
2. Consolidated Quarterly Financial Statements and Primary Notes............................................................................................
(1) Consolidated Quarterly Balance Sheets………………………………………………………………………...................
(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income..........
(Consolidated Quarterly Statements of Profit or Loss)(For the nine months ended December 31, 2021)………………………………………………………………….....
(Consolidated Quarterly Statements of Comprehensive Income)(For the nine months ended December 31, 2021)…………………………………………………………………….
(3) Consolidated Quarterly Statements of Cash Flows ……………………………………………………………………….
(4) Notes to Consolidated Quarterly Financial Statements…………………………………………………………………...
(Notes on Premise of Going Concern) …………………………………………………………………………………..
(Notes in case of Changes in Marked Amount of Shareholders’ Equity)………………………………………………..
(Changes in Subsidiaries during the nine months ended December 31, 2021) ………………………………………....
(Changes in Accounting Policies) ………………………………………………..…………..…………..………….….
(Additional Information)………………………………………………..…………..…………..…………..…………...
(Segment Information)……………………………………………………………………………..……………….…...
3. Supplementary Information…………………………………………………………………………………………………..
(1) Trends in Key Indicators for Business Management……………………………………………………………………..
(2) Comparative Consolidated Statement of Income ………………………………………………………………………..
(3) Comparative Statement of Income Relating to Consolidated Financial Forecasts……………………………………….

- 1 -

2
2
2
2
2
4
4
6
6
7
8
9
9
9
9
9
9
9
10
10
11
12

The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)
1. Overview of Financial Results for the nine months ended December 31, 2021
(1) Overview of Financial Results
The outlook for the global economy in the third quarter of the current fiscal year is uncertain due to the prolonged trade friction
between the U.S. and China and the impact of the new Coronavirus disease (COVID-19).
Against these circumstances, Takara Bio Group is promoting initiatives to advance the development of fundamental biologics
development technologies and become a biologics development company that continuously creates new modalities through theReagents and Instruments and CDMO business under the six-year Long-Term Management Plan FY2026, which ends in fiscal
2026, and the three-year Medium-Term Management Plan FY2023, which ends in fiscal 20231.
In the third quarter of the fiscal year under review, although sales of Instruments and Gene Therapy decreased year on year, salesof Reagents and CDMO increased year on year. Especially in Reagents, in addition to sales of reagents for general research which
are on a recovery trend, PCR test-related products for the new Coronavirus increased. Net sales increased to ¥45,659 million (up54.5% year on year). Cost of sales increased to ¥11,559 million (up 39.3% year on year) due to such as an improvement in the costof sales ratio in CDMO, and gross profit increased to ¥34,100 million (up 60.5% year on year). Selling, general and administrative(SG&A) expenses were ¥14,174 million (up 13.8% year on year), mainly due to an increase in personnel expenses and R&D
expenses. Operating profit was ¥19,926 million (up 126.7% year on year).
As a result of the increase in operating profit, ordinary profit increased to ¥20,154 million (up 126.0% year on year), income
before income taxes and others increased to ¥20,114 million (up 140.6% year on year), and net income attributable to owners of theparent increased to ¥14,364 million (up 150.8% year on year).
Since our group is a single segment, the disclosure by segment is omitted.
(2) Overview of Financial Position
Total assets at the end of the third quarter under review were ¥106,116 million, an increase of ¥16,365 million from the end of theprevious fiscal year. This was mainly due to an increase of ¥9,358 million in cash and deposits and an increase of ¥5,609 million
in property, plant and equipment resulting from interior finishing work for a new office building of Takara Bio USA, Inc. and ouracquisition of manufacturing facilities.
Total liabilities at the end of the third quarter under review were ¥16,660 million, an increase of ¥1,212 million from the end of
the previous fiscal year. This was mainly due to an increase of ¥1,971 million in other current liabilities, despite a decrease of¥769 million in notes and accounts payable trade.
Total net assets at the end of the third quarter under review were ¥89,455 million, an increase of ¥15,153 million from the end of
the previous fiscal year. This was mainly due to an increase of ¥12,437 million in retained earnings and an increase of ¥2,615
million in foreign currency translation adjustments due to the yen's depreciation.
(3) Overview of Cash FlowsNet cash provided by operating activities amounted to ¥15,401 million, an increase of ¥7,423 million from the same period of theprevious fiscal year. This was mainly due to attributable to income before income taxes and others of ¥20,114 million, cash
inflow from depreciation and amortization of ¥2,606 million, income taxes paid of ¥5,532 million, and cash outflow from anincrease in inventories of ¥1,322 million.
Net cash used in investing activities amounted to ¥13,380 million, an increase of ¥11,705 million from the same period of theprevious fiscal year. This was mainly due to payments into time deposits of ¥10,781 million, purchase of tangible and intangible
fixed assets of ¥8,732 million, and proceeds from subsidies received of ¥3,960 million and withdrawal of time deposits of ¥2,215
million.
Net cash used in financing activities amounted to ¥2,034 million, an increase of ¥966 million from the same period of theprevious fiscal year, mainly due to cash dividends paid of ¥1,923 million.
As a result of the above, the balance of cash and cash equivalents at the end of the third quarter of the current fiscal year,
including the effect of exchange rate changes on cash and cash equivalents, increased by ¥626 million from the end of theprevious fiscal year to ¥23,935 million.
(4) Qualitative Information Regarding Consolidated Forecasts
The financial forecast announced in the second quarter consolidated financial statements on November 9, 2021 have beenrevised. For details, please refer to "Notice Concerning Forecast Revisions of Financial Results and Dividend (Dividend
Increase)" announced today (February 10, 2022).

1

FY2026 and FY2023 refer to the fiscal year ending March 31, 2026 and 2023, respectively.
- 2 -The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)
For comparison of the revised consolidated financial forecasts with the previous fiscal year's results and the previous financial
forecasts, please refer to the "Comparative Statement of Income Relating to Consolidated Financial Forecasts" on page 12.

- 3 -The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)
2. Consolidated Quarterly Financial Statements and Primary Notes(1) Consolidated Quarterly Balance Sheets(Millions of yen)
As of Mar. 31, 2021
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation
Machinery, equipment and vehicles, net
Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net
LandConstruction in progress
Others
Accumulated depreciation
Others, net
Total Property, plant and equipment
Intangible assets
Goodwill
Other
Total intangible assets
Investments and other assets
Investments and other assets
Total investments and other assets
Total non-current assets
Total assets- 4 -As of Dec. 31, 2021

25,993
12,626
4,966
1,316
2,901
1,352
(41)
49,11535,352
12,622
5,411
2,131
3,429
1,146
(36)
60,057

15,670(5,147)
10,522
7,058(3,760)3,297
7,673(5,141)
2,531
8,143
3,756
1,796
(282)
1,514
29,766

23,409(5,920)17,4898,178(4,423)
3,755
9,541(5,825)
3,716
8,340
618
1,852
(395)
1,456
35,376

6,149
3,224
9,373

6,268
2,977
9,245

1,495
1,495
40,63589,7501,436
1,436
46,058106,116

The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)(Millions of yen)
As of Dec. 31, 2021

As of Mar. 31, 2021
Liabilities
Current liabilities
Notes and accounts payable-trade
Accrued income taxes
Provision
Other
Total current liabilities
Non-current liabilities
Retirement benefit liabilities
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Total shareholders' equity
Accumulated other comprehensive income
Foreign currency translation adjustment
Cumulative remeasurements of retirement
benefit
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets

- 5 -

2,077
3,146
739
7,228
13,191

1,308
3,201
736
9,199
14,446

800
1,456
2,256
15,448

795
1,418
2,214
16,66014,96532,89327,08574,945

14,96532,89339,52387,382

(529)

2,086

(234)

(198)

(763)
120
74,30289,7501,887
18589,455
106,116

The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income(Consolidated Quarterly Statements of Profit or Loss)(For the nine months ended December 31, 2021)(Millions of yen)
Nine months ended
Dec. 31, 2021

Nine months ended
Dec. 31, 2020
Net sales
Cost of sales
Gross profit
SG&A expenses
Employees' salaries and bonuses
Retirement benefit expenses
R&D expenses
Provision for doubtful accounts
Other
Total SG&A expenses
Operating profit
Non-operating income
Interest income
Foreign exchange gains
Rent income from real estate
Other
Total non-operating income
Non-operating expenses
Interest expenses
Rent expenses on real estate
Other
Total non-operating expenses
Ordinary profit
Extraordinary profit
Gain on sale of fixed assets
National subsidies
Total extraordinary profit
Extraordinary losses
Loss on disposal of fixed assets
Asset shrinkage losses
Loss on liquidation of business
OthersTotal extraordinary losses
Income before income taxes and others
Income taxes-current
Income taxes-deferred
Total income taxes
Net income
Net income attributable to non-controlling interest
Net income attributable to owners of the parent- 6 -29,5498,297
21,25145,65911,55934,100

3,313
145
3,656
305
5,039
12,460
8,791

3,846
174
4,020
365
5,766
14,17419,926

85
3
93
23
205

91
45
101
59
297

18
38
19
77
8,919

17
43
7
68
20,154

1
35
36

0
3,205
3,205

49
35
462
49
596
8,359
2,693
(83)
2,610
5,749
22
5,726

40
3,205
3,245
20,114
5,640
56
5,696
14,41854
14,364

The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)(Consolidated Quarterly Statements of Comprehensive Income)(For the nine months ended December 31, 2021)(Millions of yen)
Nine months ended
December 31, 2021

Nine months ended
December 31, 2020
Net income
Other comprehensive income
Foreign currency translation adjustment
Remeasurements of retirement benefit
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to:
Owners of the parent
Non-controlling interest

- 7 -

5,749

14,418

(834)
25
(809)
4,940

2,626
35
2,661
17,0804,923
1617,01465

The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)(3) Consolidated Quarterly Statements of Cash Flows(Millions of yen)

Nine months ended
Dec. 31, 2020
Net cash provided by (used in) operating activities
Income before income taxes and others
Depreciation and amortization
Depreciation and amortization on other
Amortization of goodwill
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in other provision
Increase (decrease) in retirement benefit liabilities
Interest income
Interest expenses
Loss (gain) on sale and retirement of fixed assets
Loss on liquidation of business
Decrease (increase) in trade receivables-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Increase (decrease) in other current liabilities
OthersSubtotalInterest and dividend income received
Income expenses paid
Income taxes paid
Subsidies received
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Proceeds from sales and redemption of securities
Purchase of property, plant and equipment andintangible assets
Proceeds from sales of property, plant and equipment
and intangible assets
Purchase of other depreciable assets
Subsidies received
OthersNet cash provided by (used in) investing activities
Net cash provided by (used in) financing activities
Dividends paid
Repayments of lease obligations
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period- 8 -Nine months ended
Dec. 31, 2021

8,359
2,421
61
367
(1)
68
5
(85)
18
48
462
(2,242)(2,003)
450
1,567
(26)
9,473
86
(18)
(1,563)
7,978

20,114
2,606
71
370
(7)
(31)
(5)
(91)
17
39
286
(1,322)
(972)
(861)
(29)
20,18693(17)(5,532)671
15,401(2,038)
3,422
2,000

(10,781)2,215-(6,994)(8,732)

14

3

(159)
2,082
(2)
(1,675)

(42)
3,960
(2)
(13,380)

(962)
(105)
(1,068)(230)
5,004
14,462
19,467(1,923)(111)(2,034)640
626
23,30823,935

The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)(4) Notes to Consolidated Quarterly Financial Statements(Notes on Premise of Going Concern)
No items to report.
(Notes in case of Changes in Marked Amount of Shareholders’ Equity)
No item to report.
(Changes in Subsidiaries during the nine months ended December 31, 2021)
From the first quarter of the current fiscal year, Takara Bio UK Ltd, newly established as a 100% subsidiary of Takara Bio Europe
S.A.S. has been included in the scope of consolidation.
(Changes in Accounting Policies)(Application of Accounting Standard for Revenue Recognition)
We adopted the "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29, March 31, 2020, hereinafter referred toas the "Accounting Standard for Revenue Recognition") from the beginning of the first quarter of the current fiscal year andrecognized revenue when control of promised goods or services is transferred to customers in an amount that is expected to bereceived in exchange for those goods or services.
With regard to the application of the Accounting Standard for Revenue Recognition, in accordance with the transitional treatment
stipulated in the provisions of paragraph 84 of the Accounting Standard for Revenue Recognition, the cumulative effect ofretrospectively applying the new accounting policy prior to the beginning of the first quarter of the current fiscal year was added toor deducted from retained earnings at the beginning of the first quarter of the current fiscal year, and a new accounting policy wasapplied from the beginning balance of the current fiscal year.
As a result, there was no impact on the profit and loss for the third quarter of the current fiscal year. In addition, there is no impact
on the balance of retained earnings at the beginning of the fiscal year.
(Additional Information)(Accounting Estimates for the Impact of the COVID-19)
At the time of preparing the consolidated financial statements for the previous fiscal year, the impact of the COVID-19 on ourGroup was generally assumed to continue for a certain period in fiscal 2021. However, based on information available at the timeof preparing the consolidated financial statements for the third quarter of the fiscal year under review, we have revised theassumption that the impact will continue for a certain period in fiscal 2022. We make estimates and judgments regarding theimpairment of goodwill and the recoverability of deferred tax assets at the end of the third quarter based on the revised assumptions.
However, no indicators of impairment have been identified for goodwill, and we have determined that no additional valuation
allowance is required for the recoverability of deferred tax assets.
Due to the high degree of uncertainty associated with the impact of the COVID-19, any change in the above assumptions could
have an impact on the Group's financial condition and results of operations.
(Segment Information)[Segment Information]
Since our group is a single segment, this information is omitted.

- 9 -The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)
3. Supplementary Information(1)Trends in Key Indicators for Business Management
1) Cash Flows(Millions of yen)
Nine months ended
Nine months ended
Year ended
Dec. 31, 2020
Dec. 31, 2021
Mar. 31, 2021
(Apr. 1, 2020 – Dec. 31, 2020) (Apr. 1, 2021 – Dec. 31, 2021) (Apr. 1, 2020 – Mar. 31, 2021)
Cash flow from operating
activities
Cash flow from investing
activities
Cash flow from financing
activities

7,978

15,401

13,943(1,675)(13,380)(3,778)(1,068)(2,034)(1,103)2) Sales Breakdown by Region(Millions of yen)
Nine months ended
Nine months ended
Year ended
Dec. 31, 2020
Dec. 31, 2021
Mar. 31, 2021
(Apr. 1, 2020 – Dec. 31, 2020) (Apr. 1, 2021 – Dec. 31, 2021) (Apr. 1, 2020 – Mar. 31, 2021)
12,42521,781
20,475

Japan
United States

5,745

7,298

7,862

China
Asia excluding Japan and
China
Europe

5,542

8,373

8,415

2,709

4,499

4,917

2,547

3,528

3,743

578

177

671

29,54945,65946,086

OthersTotal- 10 -

The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)(2) Comparative Consolidated Statement of Income(Rounded down to one million yen)
Nine months
ended

Nine months
ended

Dec. 31, 2020

Dec. 31, 2021

22,61536,998Instruments

1,113

CDMO

5,575

Y/Y
changeY/Y
Ratio(Net sales)
Reagents

14,382

63.6%

1,040

(73)

(6.6%)

7,474

1,898

34.0%

Gene therapy

243

146

(96)

(39.7%)

Total net sales

29,54945,65916,11054.5%

Net sales

29,54945,65916,11054.5%

Cost of sales

8,297

11,559

3,261

39.3%

Gross profit

21,251

34,10012,848

60.5%

SG & A expenses(Operating profit and Loss)

12,46014,174

1,713

13.8%

Transportation expenses

545

615

70

12.9%

Advertising expenses

40

43

2

6.1%

Promotion expenses

489

475

(13)

(2.9%)

R&D expenses

3,656

4,020

364

10.0%

Administrative expense, other

7,453

8,631

1,177

15.8%

274

386

112

41.0%

8,791

19,926

11,134126.7%

205

297

91

44.5%

Enterprise taxes (external standards taxation)
Operating profit(Non-operating income and Expenses)
Non-operating income
Non-operating expenses

77

68

(8)

(11.2%)

8,919

20,154

11,235126.0%

Extraordinary gains

36

3,205

3,169

-

Extraordinary losses

596

3,245

2,649

444.0%

Income before income taxes and others

8,359

20,114

11,755140.6%

Income taxes

2,610

5,696

3,086

118.2%Net income

5,749

14,4188,669

150.8%Net income (loss) attributable to non-controllinginterests

22

54

31

139.3%Net income attributable to owners of the parent

5,726

14,3648,637

150.8%

Depreciation and amortization(Property, plant and equipment and intangible assets)

2,421

2,606

185

7.7%

Ordinary profit(Extraordinary gains & Losses)

Amortization of goodwill
367
370
3
0.9%
※ From the first quarter of the current fiscal year, the names of the categories of net sales have been changed from "Research reagents","Scientific instruments" and "Contract services" to "Reagents", "Instruments" and "CDMO".

- 11 -

The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT+8)(3) Comparative Statement of Income Relating to Consolidated Financial Forecasts(Rounded down to one million yen)
Year
ended
Mar. 31,2021
ActualYear
endingMar. 31,2022
Previous
forecast

Year
endingMar. 31,2022
Current
forecast

Reagents

35,18946,37552,21317,023

48.4%

5,837

12.6%

Instruments

1,726

1,388

1,354

(372)

(21.5%)(34)(2.5%)CDMO

Y/Y
ChangeY/Y
Ratio

Previous
forecast
ChangePrevious
forecast
Ratio(Net sales)

8,901

11,388

11,283

2,381

26.8%

(105)

(0.9%)

Gene therapy

268

146

148

(119)

(44.5%)

2

1.5%

Total Net Sales

46,08659,30065,00018,913

41.0%

5,700

9.6%

Net sales

46,08659,30065,00018,913

41.0%

5,700

9.6%

Cost of sales

14,214

18,797

18,524

4,310

30.3%

(272)

(1.5%)

Gross profit

31,87240,502

46,475

14,603

45.8%

5,972

14.7%

SG & A expenses

17,91920,502

20,475

2,556

14.3%

(27)

(0.1%)

Transportation expenses

742

865

865

122

16.6%

(0)

(0.1%)

Advertising expenses

57

63

58

0

1.4%

(5)

(8.2%)(Operating profit and Loss)

Promotion expenses
R&D expenses
Administrative expenses, other
Enterprise taxes(external standards taxation)
Operating profit(Non-operating income andExpenses)Non-operating income
Non-operating expenses
Ordinary profit

676

759

683

6

1.0%

(76)

(10.0%)

5,545

5,974

6,162

616

11.1%

187

3.1%

10,496

12,346

12,186

1,690

16.1%

(159)

(1.3%)

401

493

520

118

29.6%

27

5.5%

13,95220,00026,00012,047

86.3%

6,000

30.0%

308

317

293

(14)

(4.7%)(23)(7.4%)

101

117

93

(7)

(7.6%)(23)(20.2%)

14,15920,20026,20012,040

85.0%

6,000

29.7%

518

4,934

4,821

4,303

829.8%(112)(2.3%)

1,125

4,999

4,925

3,800

337.7%(73)(1.5%)

13,552

20,13526,095

12,542

92.5%

5,960

29.6%

3,971

5,979

7,536

3,565

89.8%

1,556

26.0%

9,581

14,155

18,559

8,977

93.7%

4,404

31.1%

34

55

59

24

72.9%

4

7.4%

9,547

14,10018,500

8,952

93.8%

4,400

31.2%

3,220

3,623

3,534

314

9.8%

(89)

(2.5%)

486

496

500

14

2.9%

3

0.7%

(Extraordinary gains & Losses)
Extraordinary gains
Extraordinary losses
Income before income taxes
and others
Income taxes
Net income
Net income (loss) attributable
to non-controlling interests
Net income attributable toowners of parent
Depreciation and amortization(Property, plant andequipment and intangible
assets)Amortization of goodwill※

From the first quarter of the current fiscal year, the names of the categories of net sales have been changed from "Research reagents","Scientific instruments" and "Contract services" to "Reagents", "Instruments" and "CDMO".

- 12 -